KAM
ARLZ

Kavi Asset Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Kavi Asset Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-313,627
Closed -$1.52M – 41
2016
Q3 		$1.52M Hold
313,627
– – 1.31% 19
2016
Q2 		$1.03M Hold
313,627
– – 0.83% 26
2016
Q1 		$1.11M Buy
+313,627
New +$1.62M 0.87% 28

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kavi Asset Management's ARLZ Position: Q4 2016 in Review

Kavi Asset Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2016, closing a stake of 313,627 shares — an estimated $1.52M sold.

Kavi Asset Management first reported a position in ARLZ in Q1 2016 and held it in 3 quarters. The position peaked at $1.52M in Q3 2016. 83 funds tracked by Wall St. Rank hold ARLZ as of Q4 2016.

  • Kavi Asset Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
  • Kavi Asset Management sold 313,627 Aralez Pharmaceuticals Inc. shares in Q4 2016, an estimated $1.52M.
  • Kavi Asset Management first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 3 quarters.
  • Kavi Asset Management's Aralez Pharmaceuticals Inc. position peaked at $1.52M in Q3 2016.
  • 83 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2016.

Based on Kavi Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.